AUPH News and Press, Aurinia Pharmaceuticals Inc From 09/13/19

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has entered into an Open Market Sales Agreement wi...

In response to receiving a favorable analyst rating, shares of Aurinia Pharmaceuticals   (NASDAQ: AUPH) , a clinical-stage biopharmaceutical company, rose 12% as of 3:55 p.m. EDT on Tuesday. Investors can thank Justin Kim, an analyst at Oppenheimer, for today's double-digit...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $14 (141% upside) price target at Oppenheimer. Shares up  4%  premarket. More news on: Aurinia Pharmaceuticals Inc., Homology Medicines, Inc., IDEAYA Biosciences, Inc., Healthcare stocks news, Stocks on ...

Gainers:  LAKE   +13.5% . ASPU   +10.2% . CVIA   +4.4% . AUPH   +2.6%.  BNFT   +2.5% . More news on: Lakeland Industries, Inc., Aspen Group, Inc., Covia Holdings Corporation, Stocks on the move, , News on ETFs Read more ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21 st Annual H.C. Wainwright Global Investment Conference on Monday, September...

The Need The upcoming milestone at Aurinia Pharmaceuticals ( AUPH ), starting in Q4/2019, is the Phase 3 data readout for the Lupus Nephritis ((LN)) trial that could validate voclosporin ( formerly ISA247) as first-line therapy in adjunct with steroids for LN. Meaning that voclosporin could...

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this Read more ...

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with their 2019 Q2 earnings Read more ...

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2019 Results Earnings Conference Call August 06, 2019, 04:30 PM ET Company Participants Glenn Schulman - Investor Relations Peter Greenleaf - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medical...

Aurinia Pharma (NASDAQ: AUPH ): Q2 GAAP EPS of -$0.17 misses by $0.01 . Revenue of $0.03M in-line (flat Y/Y). Shares -0.33% . Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,